Impact of OKT3 treatment for steroid resistant rejection of renal allografts: the long-term outcome at a single center

Saved in:
Bibliographic Details
Published inTransplantation proceedings Vol. 31; no. 7; pp. 2870 - 2871
Main Authors Inui, M, Tanabe, K, Ishikawa, N, Tokumoto, T, Harano, M, Otsubo, S, Suzuki, K, Goya, N, Yagisawa, T, Nakazawa, H, Fuchinoue, S, Toma, H
Format Journal Article Conference Proceeding
LanguageEnglish
Published New York, NY Elsevier Inc 01.11.1999
Elsevier Science
Subjects
Actuarial Analysis
Acute Disease
Adult
Antilymphocyte Serum - therapeutic use
Biological and medical sciences
Creatinine - blood
Drug Resistance
Drug Therapy, Combination
Follow-Up Studies
Graft Rejection - drug therapy
Graft Rejection - epidemiology
Graft Survival
Guanidines - therapeutic use
Humans
Immunomodulators
Immunosuppressive Agents - therapeutic use
Kidney Transplantation - immunology
Kidney Transplantation - mortality
Kidney Transplantation - physiology
Medical sciences
Methylprednisolone - therapeutic use
Middle Aged
Muromonab-CD3 - therapeutic use
Pharmacology. Drug treatments
Retrospective Studies
Survival Analysis
Time Factors
Treatment Outcome
Muromonab-CD3
Drug combination
Chemotherapy
Prognosis
Antilymphocyte globulin
Indication
Immunotherapy
T-Lymphocyte
Immunosuppressive agent
Long term
Negative therapeutic reaction
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0041-1345
1873-2623
DOI:10.1016/S0041-1345(99)00596-5